Exploiting Recent Trends in the Treatment of Androgenic Alopecia Through Topical Nanocarriers of Minoxidil

This study reported that encapsulating minoxidil in transferosomes and transethosomes can enhance skin permeability and drug retention compared to its conventional formulation, potentially increasing efficacy in androgenic alopecia treatment while reducing side effects, especially when transethosomes contain oleic acid.

This study observed that minoxidil-loaded nanoparticles significantly enhanced skin penetration and hair regrowth in mice within three weeks, without ethanol and propylene glycol, suggesting they are a promising delivery method for treating hair loss.

This study suggests that a nanostructured lipid carrier formulation delivering minoxidil and latanoprost may enhance effectiveness and tolerability in treating alopecia by targeting hair follicles.

This study investigated the physicochemical properties of polystyrene-b-poly(acrylic acid) nanovesicles coated with modified chitosans, finding that they can effectively control surface charge and potentially serve as drug delivery carriers with a 50.7% encapsulation efficiency for minoxidil.

This review discusses lipid nanoparticle-based cosmetics, emphasizing their potential in protecting skin from radiation and treating conditions like atopic dermatitis and psoriasis with synthetic and natural antioxidants. It highlights recent research on these formulations' effectiveness in alleviating skin disorders and enhancing skin health.

This study found that topical minoxidil 5% gel and spironolactone 1% gel were both effective treatments for androgenetic alopecia, with a combination of both providing the best clinical response and achieving 100% effectiveness among participants.

This study found that nano-sized minoxidil formulations significantly increased skin penetration and follicular drug delivery for alopecia areata treatment, compared to conventional ethanol-based solutions, and demonstrated effective controlled release over six hours.

This study found that finasteride- and minoxidil-loaded nanoparticles in a gel improved skin permeability and drug retention, suggesting a promising approach for topical alopecia treatment with reduced dosing frequency and side effects.

This study investigated a liposomal hydrogel system for delivering minoxidil and tretinoin to treat androgenic alopecia, finding that the system enhanced skin permeation of minoxidil while retaining tretinoin on the skin and was non-irritating in animal tests, suggesting its potential effectiveness.

This study investigated the use of Minoxidil encapsulated in HA-PLGA nanoparticles for alopecia treatment and found that these nanoparticles efficiently delivered the drug to hair follicle cells without significant cytotoxicity, offering a potential transdermal delivery method for various diseases.

This study found that minoxidil nanoparticles increased drug delivery to hair follicles and improved hair growth more effectively in mice than conventional minoxidil formulations.

This study found that 5% topical minoxidil was moderately more effective at increasing hair regrowth than 10% minoxidil and placebo in men with androgenetic alopecia.

This meta-analysis found that dutasteride was more effective than finasteride in increasing hair count and improving photographic assessments for men with androgenetic alopecia, while both drugs had similar rates of sexual dysfunction-related adverse effects.

This study observed that androgenetic alopecia significantly impacts the quality of life in males, with personal relationships being notably affected, based on Dermatology Life Quality Index and hair-specific Skindex-29 assessments.

This study reported that oleic acid-based nanovesicles improve follicular delivery and reduce side effects of minoxidil compared to traditional MXD lotions.

This review discusses the research supporting the approval and use of minoxidil for androgenic alopecia and reports no new clinical results, emphasizing recent findings and developments.

This study found that a topical solution combining 0.25% finasteride with 3% minoxidil significantly improved hair growth, as measured by hair density, diameter, and global assessment, in men with androgenetic alopecia, compared to 3% minoxidil alone, over 24 weeks without systemic adverse effects reported.

This review finds preliminary evidence suggesting that topical finasteride may significantly reduce hair loss and increase hair counts in treating androgenetic alopecia, with a promising safety profile.

This study demonstrated that minoxidil-encapsulated PLLGA nanoparticles significantly increased minoxidil delivery to hair follicles compared to a minoxidil aqueous solution in mice.

This study found that co-delivery of minoxidil and caffeine in transfersomes with an optimized polysorbate formulation enhanced hair length and weight in vivo.

This study found that the MXD/HP-β-CD GEL formulation promoted greater hair growth and improved gene expression related to hair growth in male rats compared to MXD solution or control groups.

This study found that using 2-hydroxypropyl-ß-cyclodextrin (HP-ß-CD) to encapsulate minoxidil can create a stable aqueous solution, potentially replacing the need for organic solvents in topical treatments for androgenic alopecia.

This study reported that squarticles, nanoparticle carriers made from sebum-derived lipids, significantly enhanced minoxidil delivery to hair follicles in vitro, increasing follicular uptake sevenfold and minimizing systemic absorption compared to a free control solution, while showing good skin tolerability.

Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.

This study found that nanostructured lipid carriers enhanced the skin penetration and retention of minoxidil compared to solid lipid nanoparticles, suggesting they could be a promising method for topical delivery.

This review discusses various classification systems for patterned hair loss in both sexes and reports no new clinical findings, highlighting the Hamilton-Norwood and Ludwig systems as the most commonly used.

This study developed minoxidil sulphate-loaded chitosan nanoparticles that doubled drug delivery to hair follicles in vitro compared to a control solution, suggesting potential for improved alopecia treatment.

This review addresses treatment approaches for female pattern hair loss, highlighting that combining different therapies may be more effective than single treatments, but no new results are reported.

This study evaluated new aqueous gel formulations of minoxidil without irritants and found that the calcium alginate gel showed the best performance in terms of drug release and skin permeation.

This research reported that squarticles, nanoparticles made from sebum-derived lipids, enhanced the follicular delivery and skin accumulation of diphencyprone and minoxidil, indicating effective drug deposition with reduced systemic absorption in alopecia treatment.

This study found that minoxidil-loaded niosomes with a Span 60 and cholesterol ratio of 1:2 significantly increased skin retention of minoxidil compared to control gel.

This study suggests that a hair follicle enzyme assay may predict response to minoxidil treatment for androgenetic alopecia with high sensitivity and specificity in a preliminary analysis.

This study found that the nanostructured lipid carrier gel containing minoxidil showed good consistency and a prolonged drug release in vitro, suggesting potential for treating alopecia.

This study found that moderate to severe androgenetic alopecia is an independent predictor of increased mortality risk from diabetes mellitus and heart disease in both sexes.

This review discusses nanoparticle-based topical delivery systems for treating skin diseases and presents no new clinical findings; it emphasizes natural polymer-based nanoparticles and future applications like targeted drug delivery.

This review describes minoxidil's hair regrowth mechanism and discusses dermatological applications, but reports no new clinical results, emphasizing the need for regular use and addressing allergic reactions.

This study found that solid lipid nanoparticles with minoxidil were as effective as commercial solutions for skin penetration and were non-corrosive, indicating potential for hair loss treatment.

This study found that liposomes coated with cationic polymers, chitosan and Eudragit EPO, showed improved physicochemical stability and enhanced skin diffusion of aciclovir and minoxidil compared to uncoated liposomes.

This study found that using monoolein cubic phase nanoparticles with an entrapped hydroxypropyl β-cyclodextrin/minoxidil complex increased minoxidil skin permeation, but minoxidil retention in the skin was higher with a traditional solution.

This study found that polymeric nanoparticles retained more minoxidil and facilitated superior drug permeation compared to lipid nanoparticles, although premature drug release affected formulation performance.

This study found that penetration enhancer-containing vesicles significantly improved minoxidil delivery to the skin compared to traditional liposomes and penetration enhancer-containing ethanolic solutions, with deformability linked to enhanced deposition.

In this study, niosomal formulations enhanced minoxidil skin accumulation compared to commercial and control solutions, suggesting a potential improvement for topical delivery in hair loss treatment.

Minoxidil topical foam is a better, less irritating treatment for hair loss.

This study found that human hair follicles express ATP-sensitive potassium channels, suggesting that minoxidil acts on these channels and that drugs targeting them may treat hair disorders.

This study found that liposomal formulations improved minoxidil delivery to skin layers compared to niosomes and a control solution, suggesting enhanced potential for topical hair loss treatment.

This review summarizes findings on the use of ethosomes for enhanced transdermal drug delivery and reports no new clinical results.

This study evaluated four minoxidil gel formulations for alopecia treatment, finding similar drug release across membranes and stability over three months, with no skin irritation observed in mice.

This article reviews the clinical, psychological, and management aspects of androgenetic alopecia in men, stating that it can be effectively managed by generalist clinicians with pharmacotherapy and surgical advancements.

This article reviews the historical developments in understanding and treating male pattern hair loss, emphasizing the role of dihydrotestosterone and 5α-reductase inhibitors, but reports no new clinical findings.

This study found that neutral liposomes were most effective at delivering minoxidil into pilosebaceous units compared to other tested formulations.

This article reviews the mechanisms by which minoxidil stimulates hair growth and reports no new clinical findings.

This review discusses the genetic factors contributing to androgenetic alopecia and highlights the potential for developing more effective therapies based on recent discoveries, but reports no new clinical results.

This article reviews expert opinions on combining pharmacologic treatments like minoxidil with hair transplantation, reporting improved hair density and regrowth in patients with partially functioning follicles.

This study suggests that miniaturization in pattern hair loss may occur abruptly and can be reversed with treatment, as supported by histologic evidence in finasteride-responsive patients.

Genetics and hormones cause hair loss; finasteride treats it safely.

This study found that minoxidil significantly increases VEGF mRNA and protein expression in dermal papilla cells, suggesting a role in enhancing hair follicle vascularization in androgenetic alopecia.

In this study, minoxidil sulfate was found to relax norepinephrine-induced contractions in rabbit mesenteric arteries, possibly by acting as a K+ channel agonist, but it did not relax K+-induced contractions.

In this study, minoxidil treatment was associated with an increase in nonvellus scalp hairs, but this effect was not sustained once the treatment was stopped.

Minoxidil helps hair growth in 63.6% of alopecia patients, with 27.3% having excellent results.

Minoxidil effectively regrows hair in male pattern baldness.